Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Boule Diagnostics AB (publ), a diagnostics company, develops, manufactures, and markets instruments and consumable products for blood diagnostics. The company provides hematology analyzers, reagents, blood controls and calibrators, and reagents rotors, as well as cleaning products under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clinical chemistry analyzer and diagnostics systems under the Exigo brand. It sells its products directly in Sweden and the United States, as well as through distributors internationally. The company serves hospitals, clinics, laboratories, healthcare centers and veterinary clinics, and other diagnostics companies. It has operations in Sweden, the United States, Mexico, and Russia. The company was founded in 1956 and is headquartered in Spånga, Sweden.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITD.
Target Price
The average target price of BOUL.ST is 6.5 and suggests 70% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell